Medical and Pharmaceutical Aerosols - Aerosols: Measurement, Dosimetry, and Health Effects - page 23

53. Purewal, T.S. Formulation of metered dose inhalers. In: Purewal, T.S. and Grant, D.J.W., eds. Metered
Dose Inhaler Technology . Interpharm Press: Buffalo Groove, IL (1998).
54. Clarke, J.G., Wicks, S.R., and Farr, S.J. Surfactant mediated effects in pressurized metered dose inhalers
formulated as suspensions. I. Drug/surfactant interactions in a model propellant system. International
Journal of Pharmaceutics 93 , 221-231 (1993).
55. Blondino, F.E. and Byron, P.R. Surfactant dissolution and water solubilization in chlorine-free liquiied
gas propellants. Drug Development and Industrial Pharmacy 24 , 935-945 (1998).
56. Harnor, K. et al. Effect of vapour pressure on the deposition pattern from solution phase metered dose
inhalers. International Journal of Pharmaceutics 95 , 111-116 (1993).
57. McDonald, K.J. and Martin, G.P. Transition to CFC-free metered dose inhalers—Into the new millen-
nium. International Journal of Pharmaceutics 201 , 89-107 (2000).
58. Forte, J. and Dibble, C. The role of international environmental agreements in metered-dose inhaler
technology changes. Journal of Allergy and Clinical Immunology 104 , s217-s220 (1999).
59. Kux, L. Use of ozone-depleting substances; removal of essential-use designation (lunisolide, etc.).
Federal Register 75 , 19213-19241 (2010).
60. Noakes, T. Medical aerosol propellants. Journal of Fluorine Chemistry 118 , 35-45 (2002).
61. Alexander, D. and Libretto, S. An overview of the toxicology of HFA-134a (1,1,1,2-tetraluoroethane).
Human and Experimental Toxicology 14 , 715-720 (1995).
62. Emmen, H.H. et al. Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a
(1,1,1,2-tetraluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptaluoropropane) following whole-body expo-
sure. Regulatory Toxicology and Pharmacology 32 , 22-35 (2000).
63. Keller, M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. International
Journal of Pharmaceutics 186 , 81-90 (1999).
64. Vervaet, C. and Byron, P.R. Drug-surfactant-propellant interactions in HFA-formulations. International
Journal of Pharmaceutics 186 , 13-30 (1999).
65. Byron, P.R., Miller, N.C., Blondino, F.E., Visich, J.E., and Ward, G.H. Some aspects of alternative pro-
pellant solvency. In: Byron, P., Dalby, R., and Farr, S., eds. Proceedings of Respiratory Drug Delivery IV .
Interpharm Press: Buffalo Groove, IL, pp. 231-242 (1994).
66. Dickinson, P., Seville, P., Mchale, H., Perkins, N., and Taylor, G. An investigation of the solubility of
various compounds in the hydroluoroalkane propellants and possible model liquid propellants. Journal
of Aerosol Medicine 13 , 179-186 (2000).
67. Tiwari, D., Goldman, D., Dixit, S., Malick, W.A., and Madan, P.L. Compatibility evaluation of metered-
dose inhaler valve elastomers with tetraluoroethane (P134a), a non-CFC propellant. Drug Development
and Industrial Pharmacy 24 , 345-352 (1998).
68. Brambilla, G. et al. Modulation of aerosol clouds produced by pressurised inhalation aerosols.
International Journal of Pharmaceutics 186 , 53-61 (1999).
69. Dunbar, C.A., Watkins, A.P., and Miller, J.F. Theoretical investigation of the spray from a pressurized
metered-dose inhaler. Atomization and Sprays 7 , 417-436 (1997).
70. Dunbar, C., Watkins, A., and Miller, J. An experimental investigation of the spray issued from a pMDI
using laser diagnostic techniques. Journal of Aerosol Medicine 10 , 351-368 (1997).
71. Leach, C. Effect of formulation parameters on hydroluoroalkane-beclomethasone dipropionate drug
deposition in humans. Journal of Allergy and Clinical Immunology 104 , s250-s252 (1999).
72. Dalby, R.N. Possible replacements for CFC-propelled metered-dose inhalers. Medical Device Technology
2 , 21-25 (1991).
73. Sommerville, M.L., Cain, J.B., Johnson Jr, C.S., and Hickey, A.J. Lecithin inverse microemulsions for
the pulmonary delivery of polar compounds utilizing dimethylether and propane as propellants (2000).
At http://informahealthcare.com/doi/abs/10.1081/PDT-100100537
74. Clark, A.R. Medical aerosol inhalers: Past, present, and future. Aerosol Science and Technology 22 , 374
(1995).
75. Draft Guidance for Industry: Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products.
Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation
and Research, (1998). At http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/UCM070573.pdf
76. Dunbar, C., Hickey, A.J., and Holzner, P. Dispersion and characterization of pharmaceutical dry powder
aerosols. KONA 16 , 7-45 (1998).
77. Hindle, M. and Byron, P.R. Dose emissions from marketed dry powder inhalers. International Journal of
Pharmaceutics 116 , 169-177 (1995).